EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Etanercept ameliorates psoriasis progression through regulating high mobility group box 1 pathway

Shu Li, Guangli Li, Xiaoyan Li, Fan Wu, Ling Li

Skin Research and Technology · 2023

DOI: 10.1111/srt.13329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Skin Research and Technology, 2023. Verfasst von Shu Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Taizhou People's Hospital, Taizhou, P. R. China. Hauptthemen laut MEDLINE: HMGB1 Protein, Psoriasis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As a common skin disease, psoriasis is related to inflammation and immune response. Due to the frequent recurrence of psoriasis, the treatment of psoriasis remains a clinical challenge. As an effective tumor necrosis factor‐alpha (TNF‐α) inhibitor, etanercept has been used for the treatment of psoriasis. However, some patients with psoriasis have no response to etanercept or discontinue treatment. To improve the therapeutic effect of etanercept, searching the potential biomarkers and investigating the related mechanisms of etanercept in the treatment of psoriasis are vital. Materials and methods We stimulated HaCaT cells with lipopolysaccharide (LPS) to generate cellular psoriatic changes and established an imiquimod (IMQ)‐induced psoriasis‐like mouse model, and then used an etanercept to treat cell and mouse model.

Results

Etanercept alleviated IMQ‐induced pathological changes and inflammation, and it also decreased the protein expression of high mobility group box 1 (HMGB1), receptor for advanced glycation end‐products, and toll‐like receptor 4. Moreover, the results of in vitro experiments showed that etanercept inhibited proliferation and inflammation, and promoted cell cycle arrest and apoptosis in LPS‐treated HaCaT cells. Knockdown of HMGB1 further enhanced the inhibitory effects of etanercept on LPS‐treated HaCaT cell viability and inflammation, while overexpression of HMGB1 notably reversed the inhibitory effects of etanercept on LPS‐induced HaCaT cell viability and inflammation.

Conclusion

Etanercept inhibited proliferation and inflammation and promoted cell cycle arrest and apoptosis in LPS‐induced HaCaT cells, and etanercept ameliorated inflammation in a psoriasis‐like mouse model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HMGB1 ProteinPsoriasisAnimalsMiceDisease Models, AnimalEtanerceptImiquimodInflammationKeratinocytesLipopolysaccharidesReceptor for Advanced Glycation End Products

Stichwörter der Autor:innen

HMGB1 signaling pathwayHaCaT cellsetanerceptinflammationpsoriasis

Substanzen

EtanerceptHMGB1 ProteinImiquimodLipopolysaccharidesReceptor for Advanced Glycation End Products

Autor:innen und Institutionen

  • Department of Dermatology, Taizhou People's Hospital, Taizhou, P. R. China.
  • Internal Medicine Department, Fushun Maternal and Child Health Hospital, Fushun, P. R. China.
  • Department of Dermatology, Lianshui County People's Hospital, Huai 'an, P. R. China.

Zitieren

APA

Li, S., Li, G., Li, X., Wu, F., & Li, L. (2023). Etanercept ameliorates psoriasis progression through regulating high mobility group box 1 pathway. Skin Research and Technology. https://doi.org/10.1111/srt.13329

Vancouver

Li S, Li G, Li X, Wu F, Li L. Etanercept ameliorates psoriasis progression through regulating high mobility group box 1 pathway. Skin Research and Technology. 2023. doi:10.1111/srt.13329

BibTeX
@article{Li2023,
  author = {Li, Shu and Li, Guangli and Li, Xiaoyan and Wu, Fan and Li, Ling},
  title = {Etanercept ameliorates psoriasis progression through regulating high mobility group box 1 pathway},
  journal = {Skin Research and Technology},
  year = {2023},
  doi = {10.1111/srt.13329}
}
Kostenlos starten →